In this episode, we’re exploring how targeted intra-arterial delivery platforms are redefining the treatment of solid tumors, offering a way to bathe cancer directly in therapy while limiting systemic toxicity. Our guest is Shaun Bagai, CEO of RenovoRx, who will discuss an ongoing post-marketing registry study that is gathering real-world evidence on safety, performance, and survival outcomes for patients receiving these localized treatments.